Targeting epidermal growth factor receptor and its downstream signaling pathways by natural products: A mechanistic insight
Fuente:
Wiley Open Access
Salvato in:
| Autori principali: | , , |
|---|---|
| Natura: | Artículo Open Access |
| Pubblicazione: |
Wiley
2024
|
| Soggetti: | |
| Accesso online: | |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne!!
|
| _version_ | 1867016117941174272 |
|---|---|
| author | Rutuja Damare Kritika Engle Gautam Kumar |
| author_facet | Rutuja Damare Kritika Engle Gautam Kumar Rutuja Damare Kritika Engle Gautam Kumar |
| collection | Wiley Open Access |
| contents | Targeting epidermal growth factor receptor and its downstream signaling pathways by natural products: A mechanistic insight Rutuja Damare Kritika Engle Gautam Kumar Phytotherapy Research AbstractThe epidermal growth factor receptor (EGFR) is a transmembrane receptor tyrosine kinase (RTK) that maintains normal tissues and cell signaling pathways. EGFR is overactivated and overexpressed in many malignancies, including breast, lung, pancreatic, and kidney. Further, the EGFR gene mutations and protein overexpression activate downstream signaling pathways in cancerous cells, stimulating the growth, survival, resistance to apoptosis, and progression of tumors. Anti‐EGFR therapy is the potential approach for treating malignancies and has demonstrated clinical success in treating specific cancers. The recent report suggests most of the clinically used EGFR tyrosine kinase inhibitors developed resistance to the cancer cells. This perspective provides a brief overview of EGFR and its implications in cancer. We have summarized natural products‐derived anticancer compounds with the mechanistic basis of tumor inhibition via the EGFR pathway. We propose that developing natural lead molecules into new anticancer agents has a bright future after clinical investigation. 10.1002/ptr.8166 http://onlinelibrary.wiley.com/termsAndConditions#vor |
| doi_str_mv | 10.1002/ptr.8166 |
| format | Artículo Open Access |
| id | wiley_oa_10_1002_ptr_8166 |
| institution | Wiley Open Access |
| license_str_mv | http://onlinelibrary.wiley.com/termsAndConditions#vor |
| publishDate | 2024 |
| publisher | Wiley |
| record_format | wiley_oa |
| spellingShingle | Targeting epidermal growth factor receptor and its downstream signaling pathways by natural products: A mechanistic insight Rutuja Damare Kritika Engle Gautam Kumar Phytotherapy Research Targeting epidermal growth factor receptor and its downstream signaling pathways by natural products: A mechanistic insight Rutuja Damare Kritika Engle Gautam Kumar Phytotherapy Research AbstractThe epidermal growth factor receptor (EGFR) is a transmembrane receptor tyrosine kinase (RTK) that maintains normal tissues and cell signaling pathways. EGFR is overactivated and overexpressed in many malignancies, including breast, lung, pancreatic, and kidney. Further, the EGFR gene mutations and protein overexpression activate downstream signaling pathways in cancerous cells, stimulating the growth, survival, resistance to apoptosis, and progression of tumors. Anti‐EGFR therapy is the potential approach for treating malignancies and has demonstrated clinical success in treating specific cancers. The recent report suggests most of the clinically used EGFR tyrosine kinase inhibitors developed resistance to the cancer cells. This perspective provides a brief overview of EGFR and its implications in cancer. We have summarized natural products‐derived anticancer compounds with the mechanistic basis of tumor inhibition via the EGFR pathway. We propose that developing natural lead molecules into new anticancer agents has a bright future after clinical investigation. 10.1002/ptr.8166 http://onlinelibrary.wiley.com/termsAndConditions#vor |
| title | Targeting epidermal growth factor receptor and its downstream signaling pathways by natural products: A mechanistic insight |
| topic | Phytotherapy Research |
| url | https://onlinelibrary.wiley.com/doi/10.1002/ptr.8166 |